- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01975051
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:Post-kala-azar dermal leishmaniasis is a skin disorder caused by the Leishmania donovani and usually develops after treatment for visceral leishmaniasis. The public health importance of this condition is that it plays as an inter-epidemic reservoir of visceral leishmaniasis.It is believed that the condition is associated with sodium stibogluconate (SSG) monotherapy for visceral leishmaniasis; however evidence is lacking to support this. Further no study has been carried out to explore the pathogenesis of PKDL in Bangladesh. Also no information is available related to development of PKDL after treatment of VL with miltefosine monotherapy in Bangladesh.Better knowledge on pathogenesis of PKDL will help to predict and design intervention to prevent the development of PKDL. This will help to reduce the numbers of inter-epidemic reservoir for VL and hence will contribute to the national kala-azar elimination program.
Objectives:1. To investigate the incidence of PKDL after SSG or Miltefosine mono-therapy for VL; 2. To investigate serum level of IL-10, TGF-β and markers of lipid metabolism (serum cholesterols) before and after treatment of PKDL; 3. To investigate the mRNA expression of IL-10, TGF-β in skin lesion of PKDL; 4. To investigate the association of gene polymorphism of IL-10, TGF-β and PKDL; 5. To develop a new diagnostic tool for diagnosis of PKDL by detection of LD antigen in the skin tissue by punch biopsy using immunofluorescence technique; and, 6. To investigate leishmania antigens and anti-leishmania antibodies in urine before and after treatment of PKDL and evaluate possibility to use them as diagnostic tools.
Methods:1. The incidence of PKDL after treatment for VL will be investigated through studying a retrospective cohort which will be identified by cross-sectional survey; 2. serum level of cytokines and lipid profile will be measured respectively by cytometric bed-array and autoanalyzer before and after treatment for PKDL; 3. mRNA expression of cytokines will be measured real-time PCR before and after treatment for PKDL; 4. gene polymorphism will be investigated by DNA sequencing; 5. the new diagnostic tool will be developed using immunofluorescence technique; and, 6. urine antigens and antibodies will be detected by ELISA.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Dhaka, Bangladesh, 1212
- Dinesh Mondal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of Visceral Leishmaniasis
- Presence of hypopigmented rash
- Rk39 strip test positive
- Written informed consent from the participant
Exclusion Criteria:
- Any medical condition that may affect the safety of the patient during study procedure
- Any condition which comprises the ability to comply the study procedure
- Presence of splenomegaly
- Posotive skin smear for mycobacterium leprae
- Positive skin smear for fungus
- Pregnancy test positive
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Miltefosine
Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
|
Tablet Miltefosine 100 mg in two devided doses for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore the association of treatment regimens for visceral leishmaniasis, host immunological, genetical and nutrition factors with Post-kala-azar Dermal Leishmaniasis (PKDL)
Time Frame: Three years
|
1. PKDL burden among VL patients treated with SSG and miltefosine in the past; 2. Association of serum level of IL-10, TGF-β and serum level of cholesterols before and after treatment of PKDL; 3. mRNA expression of IL-10, TGF-β in skin lesion before and after treatment; 4. association of gene polymorphism of IL-10, TGF-β and PKDL; 5. diagnostic sensitivity of immunofluorescence technique compared to skin slit examination and PCR; and, 6. titer of urine antigens and antibodies before and after treatment of PKDL.
|
Three years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Dinesh Mondal, MB; MD; PhD, International Centre for Diarrhoeal Disease Research, Bangladesh
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Euglenozoa Infections
- Leishmaniasis
- Leishmaniasis, Visceral
- Anti-Infective Agents
- Antineoplastic Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Miltefosine
Other Study ID Numbers
- PR-12057
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-kala-azar Dermal Leishmaniasis
-
IDRICompletedPost Kala Azar Dermal LeishmaniasisSudan
-
Medecins Sans Frontieres, NetherlandsCompletedPost-kala-azar Dermal Leishmaniasis
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
University of YorkWellcome Trust; European and Developing Countries Clinical Trials Partnership... and other collaboratorsWithdrawnPost-kala-azar Dermal Leishmaniasis
-
International Centre for Diarrhoeal Disease Research...Thrasher Research FundCompleted
-
Drugs for Neglected DiseasesUnknown
-
EpicentreDrugs for Neglected Diseases; European and Developing Countries Clinical Trials... and other collaboratorsRecruitingLeishmaniasis | Leishmaniasis, Visceral | Post-kala-azar Dermal LeishmaniasisSouth Sudan
-
IDRIBill and Melinda Gates FoundationCompletedVisceral Leishmaniasis | Post-kala-azar Dermal LeishmaniasisIndia
-
London School of Hygiene and Tropical MedicineUniversity Hospital, Geneva; International Centre for Diarrhoeal Disease Research... and other collaboratorsCompletedVisceral Leishmaniasis | Kala AzarIndia, Nepal
-
AB FoundationAEterna ZentarisTerminated